Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612285 · ClinicalTrials.gov registry record · Phase 2
Study of SNX-5422 in TP53 Null Cancers
A Phase 2 study, sponsored by Esanex.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02612285: Clinical Trial Phase 2 study, sponsored by Esanex.
NCT02612285 is a Phase 2 study that was terminated before completion, run by Esanex. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02612285, a Phase 2 study, was terminated before completion, sponsored by Esanex.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
SNX-5422 is a pro-drug of SNX-2112, a potent, highly selective, small-molecule inhibitor of the molecular chaperone heat shock protein 90 (Hsp90). Initial in vitro evidence supports that SNX-5422 may be active against TP53 null tumors irrespective of tumor type .
Primary Outcome
Effect of SNX-5422 on tumor progression. Complete remissions plus partial remissions plus stable disease at ≥6 months) will be listed by subject. Tumor measurements made using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or appropriate hematological malignancy criteria.
Interventions
- DRUG SNX-5422
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-03 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Why NCT02612285 stopped before completion
NCT02612285 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which SNX-5422 is the first listed.
NCT02612285 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02612285 about?
NCT02612285 is a clinical study titled "Study of SNX-5422 in TP53 Null Cancers". SNX-5422 is a pro-drug of SNX-2112, a potent, highly selective, small-molecule inhibitor of the molecular chaperone heat shock protein 90 (Hsp90). Initial in vitro evidence supports that SNX-5422 may be active against TP53 null tumors irrespective of tumor type .
What is the current status of trial NCT02612285?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-03. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02612285?
The interventions under investigation include: SNX-5422 (DRUG).
Who is sponsoring clinical trial NCT02612285?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02612285's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia